List of Excipients in API tofacitinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing tofacitinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | XELJANZ | tofacitinib | 0069-1001 | CELLULOSE, MICROCRYSTALLINE | |
| Pfizer Laboratories Div Pfizer Inc | XELJANZ | tofacitinib | 0069-1001 | CROSCARMELLOSE SODIUM | |
| Pfizer Laboratories Div Pfizer Inc | XELJANZ | tofacitinib | 0069-1001 | HYPROMELLOSE 2910 | |
| Pfizer Laboratories Div Pfizer Inc | XELJANZ | tofacitinib | 0069-1001 | LACTOSE MONOHYDRATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Showing 1 to 4 of 4 entries
Excipients in ANDA-approved (generic) drugs containing tofacitinib
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 | D&C RED NO. 27 ALUMINUM LAKE |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 | ETHYLCELLULOSE |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 | FD&C BLUE NO. 2--ALUMINUM LAKE |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 | FERRIC OXIDE RED |
| >Company | >Ingredient | >NDC | >Excipient |
Showing 1 to 4 of 4 entries
Detailed excipient profiles for tofacitinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
tofacitinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: CROSCARMELLOSE SODIUM
tofacitinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: D&C RED NO. 27 ALUMINUM LAKE
tofacitinib drug variants containing D&C RED NO. 27 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing D&C RED NO. 27 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: ETHYLCELLULOSE
tofacitinib drug variants containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: FD&C BLUE NO. 2--ALUMINUM LAKE
tofacitinib drug variants containing FD&C BLUE NO. 2--ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing FD&C BLUE NO. 2--ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: FERRIC OXIDE RED
tofacitinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: FERROSOFERRIC OXIDE
tofacitinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: HYPROMELLOSE 2208
tofacitinib drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: HYPROMELLOSE 2910
tofacitinib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 4 of 4 entries
tofacitinib drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Showing 0 to 0 of 0 entries
Excipient focus: LACTOSE MONOHYDRATE
tofacitinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 4 of 4 entries
tofacitinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Showing 0 to 0 of 0 entries
Excipient focus: MAGNESIUM STEARATE
tofacitinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 4 of 4 entries
tofacitinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Showing 0 to 0 of 0 entries
Excipient focus: POLYETHYLENE GLYCOL 3350
tofacitinib drug variants containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing POLYETHYLENE GLYCOL 3350
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: POLYETHYLENE GLYCOL 4000
tofacitinib drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: PROPYLENE GLYCOL
tofacitinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: SHELLAC
tofacitinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: SODIUM LAURYL SULFATE
tofacitinib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Excipient focus: TITANIUM DIOXIDE
tofacitinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 4 of 4 entries
tofacitinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| No data available in table | ||
| >Company | >Ingredient | >NDC |
Showing 0 to 0 of 0 entries
Excipient focus: TRIACETIN
tofacitinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | tofacitinib | 0069-1001 |
| US Pharmaceuticals | tofacitinib | 63539-012 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
tofacitinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc. | tofacitinib | 70710-1353 |
| Zydus Lifesciences Limited | tofacitinib | 70771-1627 |
| >Company | >Ingredient | >NDC |
Showing 1 to 2 of 2 entries
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
